Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program

Farooq, Vasim; Vranckx, Pascal; Mauri, Laura; Cutlip, Donald E; Belardi, Jorge; Silber, Sigmund; Widimsky, Petr; Leon, Martin; Windecker, Stephan; Meredith, Ian; Negoita, Manuela; van Leeuwen, Frank; Neumann, Franz-Joseph; Yeung, Alan C; Garcia-Garcia, Hector M; Serruys, Patrick W (2013). Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program. Heart, 99(9), pp. 626-633. BMJ Publishing Group 10.1136/heartjnl-2012-303368

Text 626.full.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (175kB)

BACKGROUND

Overlapping first generation sirolimus- and paclitaxel-eluting stents are associated with persistent inflammation, fibrin deposition and delayed endothelialisation in preclinical models, and adverse angiographic and clinical outcomes--including death and myocardial infarction (MI)--in clinical studies.

OBJECTIVES

To establish as to whether there are any safety concerns with newer generation drug-eluting stents (DES).

DESIGN

Propensity score adjustment of baseline anatomical and clinical characteristics were used to compare clinical outcomes (Kaplan-Meier estimates) between patients implanted with overlapping DES (Resolute zotarolimus-eluting stent (R-ZES) or R-ZES/other DES) against no overlapping DES. Additionally, angiographic outcomes for overlapping R-ZES and everolimus-eluting stents were evaluated in the randomised RESOLUTE All-Comers Trial.

SETTING

Patient level data from five controlled studies of the RESOLUTE Global Clinical Program evaluating the R-ZES were pooled. Enrollment criteria were generally unrestrictive.

PATIENTS

5130 patients.

MAIN OUTCOME MEASURES

2-year clinical outcomes and 13-month angiographic outcomes.

RESULTS

644 of 5130 patients (12.6%) in the RESOLUTE Global Clinical Program underwent overlapping DES implantation. Implantation of overlapping DES was associated with an increased frequency of MI and more complex/calcified lesion types at baseline. Adjusted in-hospital, 30-day and 2-year clinical outcomes indicated comparable cardiac death (2-year overlap vs non-overlap: 3.0% vs 2.1%, p=0.36), major adverse cardiac events (13.3% vs 10.7%, p=0.19), target-vessel MI (3.9% vs 3.4%, p=0.40), clinically driven target vessel revascularisation (7.7% vs 6.5%, p=0.32), and definite/probable stent thrombosis (1.4% vs 0.9%, p=0.28). 13-month adjusted angiographic outcomes were comparable between overlapping and non-overlapping DES.

CONCLUSIONS

Overlapping newer generation DES are safe and effective, with comparable angiographic and clinical outcomes--including repeat revascularisation--to non-overlapping DES.

Interest & Impact

Downloads

8 since deposited on 19 Mar 2014
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item